Drug Sponsors

Flagship Pioneering launches Sigilon Therapeutics

Monday, June 26, 2017

Flagship Pioneering, a fully-integrated life science innovation enterprise, announced the launch of Sigilon Therapeutics. Sigilon Therapeutics is a biopharmaceutical company that discovers and develops category-defining biocompatible encapsulated cell therapies. Sigilon Therapeutics’ discovery platform combines cell engineering and revolutionary biocompatible Afibromer technology, a new class of implantable biomaterials that do not trigger fibrosis.

[Read More]

AmerisourceBergen reorganizes

Monday, June 19, 2017

AmerisourceBergen announced a new organizational structure designed to further align the organization to its customer needs in a more seamless and unified way, while supporting corporate strategy and accelerating growth. The company’s customer-facing offerings will now be aligned under two groups:

[Read More]

Irvine Scientific adds new R&D center of excellence

Wednesday, June 14, 2017

Irvine Scientific, a leader in the development and manufacture of cell culture media, announced the expansion of its Orange County, California, offices and laboratories, with the addition of a 40,000 square foot purpose-built R&D center at 17112 Armstrong Ave, Irvine, California. The growth of the company is in response to increased customer demand for Irvine Scientific’s cell culture and media reagents, and follows the significant expansion of its R&D facilities less than five years ago.

[Read More]

MSD Ireland announces 330 new jobs

Monday, June 5, 2017

MSD, known as Merck in the U.S. and Canada, will create 330 new jobs and invest €280 million over the next three years at two of its Irish manufacturing sites—important links in MSD’s global network of manufacturing plants. MSD maintains headquarters for the company and manufacturing division in the U.S.

[Read More]

Rich Pharma launches clinical site in Thailand

Monday, June 5, 2017

Rich Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, has selected a site and obtained investigator’s interest at Phramongkutklao Hospital in Bangkok, Thailand. Rich has engaged CMIC ASIA-PACIFIC, PTE. LTD. (CMIC) to assist in this project and they have already completed a site selection visit at Phramongkutklao Hospital, and the site has been cleared.

[Read More]